Gilead’s $7.8B Arcellx Purchase Is Third Oncology Acquisition
Gilead Sciences acquired Arcellx in February for $7.8 billion as its third oncology-focused buyout this year, following a $5 billion deal for Tubulis and a $2 billion-plus acquisition of Ouro Medicines. The spree aims to strengthen Gilead’s antibody–drug conjugate pipeline and offset patent expiries on its COVID-19 treatment.
1. Acquisition Details
Gilead completed a $7.8 billion purchase of Arcellx in February 2026, marking its third oncology acquisition so far this year and delivering full ownership of Arcellx’s CAR T and ADC platforms.
2. Strategic Rationale
The deal is designed to expand Gilead’s cancer treatment arm amid looming patent expirations on Veklury, reinforcing its commitment to antibody–drug conjugates after earlier 2026 acquisitions of Tubulis and Ouro Medicines.
3. Pipeline Integration
Arcellx’s ARC-SparX platform will merge with Gilead’s existing R&D in ADC development, with the former Arcellx Munich site becoming a hub for advancing lead candidates toward phase II trials by year-end.
4. Competitive Context
Drawing lessons from its 2020 $21 billion Immunomedics acquisition, Gilead now competes directly with AstraZeneca and Daiichi Sankyo’s Enhertu franchise in lung and ovarian oncology markets.